TipRanks (Mon, 25-Sep 6:30 AM ET)
PRNewswire (Wed, 6-Sep 8:30 AM ET)
PRNewswire (Thu, 10-Aug 4:05 PM ET)
PRNewswire (Thu, 27-Jul 4:05 PM ET)
PRNewswire (Fri, 21-Jul 8:00 AM ET)
PRNewswire (Tue, 18-Jul 8:00 AM ET)
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain.
Acelrx Pharmaceuticals trades on the NASDAQ stock market under the symbol ACRX.
As of September 25, 2023, ACRX stock price declined to $0.60 with 351,555 million shares trading.
ACRX has a beta of 0.65, meaning it tends to be less sensitive to market movements. ACRX has a correlation of 0.01 to the broad based SPY ETF.
ACRX has a market cap of $9.82 million. This is considered a Sub-Micro Cap stock.
Last quarter Acelrx Pharmaceuticals reported $253,000 in Revenue and -$.40 earnings per share. This beat revenue expectation by $183,000 and exceeded earnings estimates by $.13.
In the last 3 years, ACRX stock traded as high as $58.80 and as low as $.55.
The top ETF exchange traded funds that ACRX belongs to (by Net Assets): VTI, VXF, ITOT.
ACRX has underperformed the market in the last year with a price return of -86.8% while the SPY ETF gained +17.2%. ACRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.7% and -30.8%, respectively, while the SPY returned -0.6% and -2.6%, respectively.
ACRX support price is $.61 and resistance is $.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRX stock will trade within this expected range on the day.